Home › UPDATE 1-Vertex cystic fibrosis combo succeeds in key late-stage trials
 

Keywords :   


UPDATE 1-Vertex cystic fibrosis combo succeeds in key late-stage trials

2014-06-25 09:50:35| Biotech - Topix.net

A combination of Vertex Pharmaceuticals Inc's cystic fibrosis drug Kalydeco and its experimental lumacaftor succeeded in improving lung function in a pair of closely watched late-stage trials of patients with the most common genetic mutation associated with the rare lung disease.

Tags: key update combo trials

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.07Hurricane Beryl Graphics
05.07Hurricane Beryl Public Advisory Number 25A
05.07Summary for Hurricane Beryl (AT2/AL022024)
05.07Amazon at 30: What next for 'The Everything Company'?
05.07Atlantic Tropical Weather Outlook
05.07Could the 'flying piano' help transform air cargo?
05.07Eastern North Pacific Tropical Weather Outlook
04.07Hurricane Beryl Graphics
More »